“In summary, our science-led strategy is delivering compelling proof points that we are creating a sustainable innovation ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...

A legal loophole allows companies to add new additives into your food without approval from the Food and Drug Administration.

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating on November 15.Don't Miss our ...